OPS
NBIX icon

Orion Portfolio Solutions’s Neurocrine Biosciences NBIX Stock Holding History

Orion Portfolio Solutions’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$3.04M Buy
27,518
+1,615
+6% +$205K 0.03% 525
2024
Q4 		$3.54M Sell
25,903
-1,031
-4% -$128K 0.04% 435
2024
Q3 		$3.1M Sell
26,934
-221
-0.8% -$30.3K 0.03% 487
2024
Q2 		$3.74M Sell
27,155
-1,810
-6% -$248K 0.04% 399
2024
Q1 		$3.99M Sell
28,965
-490
-2% -$66.9K 0.04% 379
2023
Q4 		$3.95M Sell
29,455
-2,749
-9% -$316K 0.05% 365
2023
Q3 		$3.62M Buy
32,204
+3,993
+14% +$420K 0.04% 381
2023
Q2 		$15.3M Sell
28,211
-3,559
-11% -$348K 0.16% 125
2023
Q1 		$3.22M Buy
+31,770
New +$3.31M 0.04% 403
2020
Q3 		– Sell
-34
Closed -$4K – 1464
2020
Q2 		$4K Buy
34
+3
+10% +$332 ﹤0.01% 1568
2020
Q1 		$3K Buy
31
+6
+24% +$587 ﹤0.01% 1474
2019
Q4 		$3K Buy
+25
New +$2.62K ﹤0.01% 1422

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Orion Portfolio Solutions's NBIX Position: Q1 2025 in Review

Orion Portfolio Solutions increased its Neurocrine Biosciences (NBIX) stake by 6.2% in Q1 2025, buying an estimated $205K and bringing the position to 27,518 shares worth $3.04M. The position accounts for 0.03% of the portfolio, ranked #525.

Orion Portfolio Solutions first reported a position in NBIX in Q4 2019 and has held it in 12 quarters since. The position peaked at $15.3M in Q2 2023. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Orion Portfolio Solutions held 27,518 shares of Neurocrine Biosciences worth $3.04M as of Q1 2025.
  • Orion Portfolio Solutions bought 1,615 Neurocrine Biosciences shares in Q1 2025, an estimated $205K.
  • Neurocrine Biosciences made up 0.03% of Orion Portfolio Solutions's portfolio in Q1 2025, its #525 holding.
  • Orion Portfolio Solutions first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 12 quarters since.
  • Orion Portfolio Solutions's Neurocrine Biosciences position peaked at $15.3M in Q2 2023.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Orion Portfolio Solutions's 13F filing for Q1 2025, filed 14 May 2025.